<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:oboInOwl="http://www.geneontology.org/formats/oboInOwl#" xmlns:NCBITaxon="http://purl.obolibrary.org/obo/NCBITaxon#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:obo="http://purl.obolibrary.org/obo/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:ncbitaxon="http://purl.obolibrary.org/obo/ncbitaxon#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>                            NIH Public Access <br />                             Author Manuscript <br />                             Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01. <br />                            Published final edited form as: <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                             Expert Opin Drug Discov. 2013 December ; 8(12): . doi:10.1517/17460441.2013.845554. <br />  <br />  <br />  <br />                            Design screening drugs treatment Chagas <br />                            disease: shows promise? <br />                            Galina I. Lepesheva <br />                            Vanderbilt University, Institute Global Health, School Medicine, Center Structural <br />                            Biology, Department Biochemistry, Nashville, TN, USA <br />  <br />                            Abstract <br />                                 Introduction&#8212;Endemic Latin America, Chagas disease global <br />                                 health problem, financial viability pharmaceutical industry remains <br />                                 incurable. In 2012, antimycotic drugs inhibitors fungal sterol 14&#945;-demethylase (CYP51) &#8211; <br />                                 posaconazole ravuconazole &#8211; entered clinical trials. Availability X-ray structure the <br />                                 orthologous enzyme causative agent disease, protozoan parasite <span id='am-34' about='obo:NCBITaxon_5690' typeof='owl:Thing obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_33682 obo:NCBITaxon_5654 obo:NCBITaxon_2759 obo:NCBITaxon_5653'><span id='am-35' property="rdfs:label" content="Trypanosoma" datatype="xsd:string"></span><span id='am-36' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-37'  ></span><span id='am-38' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>Trypanosoma</span> <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                 cruzi, determined complexes posaconazole experimental protozoa- <br />                                 specific CYP51 inhibitors opens excellent opportunity improve situation. <br />                                 Areas covered&#8212;<span id='am-80' about='obo:NCBITaxon_169495' typeof='owl:Thing obo:NCBITaxon_33340 obo:NCBITaxon_33213 obo:NCBITaxon_169440 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_7147 obo:NCBITaxon_43733 obo:NCBITaxon_33154 obo:NCBITaxon_43738 obo:NCBITaxon_480117 obo:NCBITaxon_33317 obo:NCBITaxon_169449 obo:NCBITaxon_480118 obo:NCBITaxon_2759 obo:NCBITaxon_6072 obo:NCBITaxon_6960 obo:NCBITaxon_43750 obo:NCBITaxon_33208 obo:NCBITaxon_85512 obo:NCBITaxon_197562 obo:NCBITaxon_197563 obo:NCBITaxon_7203 obo:NCBITaxon_6656 obo:NCBITaxon_7496 obo:NCBITaxon_1206794 obo:NCBITaxon_88770 obo:NCBITaxon_33392 obo:NCBITaxon_169455 obo:NCBITaxon_50557 obo:NCBITaxon_43741'><span id='am-81' property="rdfs:label" content="This" datatype="xsd:string"></span><span id='am-82' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-83' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-84'  ></span>This</span> article summarizes information available PubMed Google on <br />                                 outcomes treatment chronic Chagas disease. It outlines major features the <br />                                 T. cruzi CYP51 structure possible structure-based strategies rational design novel T. <br />                                 cruzi specific drugs. <br />                                 Expert opinion&#8212;There doubt screenings alternative drug-like molecules as <br />                                 mining T. cruzi genome novel drug targets great value eventually lead to <br />                                 groundbreaking discoveries. However, newly identified molecules proceed the <br />                                 long, expensive low-yielding drug optimization process, novel potential drug targets <br />                                 validated terms essentiality druggability. CYP51 well-validated <br />                                 highly successful target clinical agricultural antifungals. With minimal investments <br />                                 final stages development/trials, T. cruzi-specific CYP51 inhibitors provide an <br />                                 immediate treatment Chagas disease, combination currently <br />                                 available drugs. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                            Keywords <br />                                 Chagas disease; drug discovery; sterol 14&#945;-demethylase (CYP51) inhibitors; sterol biosynthesis; <br />                                 structure-based drug design; <span id='am-29' about='obo:NCBITaxon_5693' typeof='owl:Thing obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_33682 obo:NCBITaxon_5654 obo:NCBITaxon_5690 obo:NCBITaxon_2759 obo:NCBITaxon_47570 obo:NCBITaxon_5653'><span id='am-30' property="rdfs:label" content="Trypanosoma cruzi" datatype="xsd:string"></span><span id='am-31'  ></span><span id='am-32' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-33' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span>Trypanosoma cruzi</span> <br />  <br />  <br />                            1. Introduction <br />                                              Chagas disease, known American trypanosomiasis, life-long infection, <br />                                              anthropozoonosis caused unicellular flagellate protozoan parasite Trypanosoma cruzi <br />                                              (<span id='am-70' about='obo:NCBITaxon_class' typeof='owl:Thing NCBITaxon:_taxonomic_rank'><span id='am-71' property="rdfs:label" content="class" datatype="xsd:string"></span><span id='am-72' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>class</span> <span id='am-51' about='obo:NCBITaxon_5653' typeof='owl:Thing obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_33682 obo:NCBITaxon_2759'><span id='am-52'  ></span><span id='am-53' property="oboInOwl:hasRelatedSynonym" content="kinetoplastids" datatype="xsd:string"></span><span id='am-54' property="oboInOwl:hasExactSynonym" content="kinetoplasts" datatype="xsd:string"></span><span id='am-55' property="oboInOwl:hasRelatedSynonym" content="Kinetoplastea" datatype="xsd:string"></span><span id='am-56' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-57' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-58' property="rdfs:label" content="Kinetoplastida" datatype="xsd:string"></span><span id='am-59' property="oboInOwl:hasRelatedSynonym" content="Protomonadida" datatype="xsd:string"></span>Kinetoplastida</span>) [1&#8211;3]. The pathogen, described 1909 Carlos Chagas, a <br />  <br />  <br />  <br />                            &#169; 2013 Informa UK, Ltd. <br />                            Galina I Lepesheva PhD, Research Associate Professor, Vanderbilt University, Institute Global Health, School Medicine, <br />                            Center Structural Biology, Department Biochemistry, 622 RRB, 23rd Pierce, Nashville, TN 37232, USA, Tel: +1 615 343 <br />                            1373; Fax: +1 615 322 4349; galina.i.lepesheva@vanderbilt.edu <br />                            Declaration interest <br />                            GI Lepesheva declares support form grant US National Institutes Health (R01 GM067871). <br />                             Lepesheva                                                                                             Page 2 <br />  <br />  <br />                                         complex life cycle, involving developmental stages: proliferative epimastigote and <br />                                         infective metacyclic trypomastigote hematophagous triatomine <span id='am-104' about='obo:NCBITaxon_29278' typeof='owl:Thing obo:NCBITaxon_81077 obo:NCBITaxon_1 obo:NCBITaxon_28384'><span id='am-105' property="rdfs:label" content="vectors" datatype="xsd:string"></span><span id='am-106' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-107' property="oboInOwl:hasDbXref" content="GC_ID:11" datatype="xsd:string"></span>vectors</span> (&#8216;kissing bugs&#8217;); <br />                                         proliferative intracellular amastigotes infective bloodstream trypomastigotes in <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         humans variety mammalian hosts (&gt; 150 <span id='am-85' about='obo:NCBITaxon_species' typeof='owl:Thing NCBITaxon:_taxonomic_rank'><span id='am-86' property="rdfs:label" content="species" datatype="xsd:string"></span><span id='am-87' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>species</span>) form disease reservoir. <br />                                         The insect stages T. cruzi develop kissing bug hindgut transmitted to <br />                                         mammals bug feces deposited blood feeding itchy bite wound or <br />                                         mucous membranes. In mammals, parasites soon exit bloodstream invade the <br />                                         cytoplasm host cells. Although various cell types infected, chronic disease is <br />                                         associated mainly cardiac enteric tissues. Non-vector-borne routes T. cruzi <br />                                         transmission include congenital (from mother child, 1 &#8211; 10% newborn babies some <br />                                         endemic countries [4]), transfusion infected blood, organ transplantation, ingestion of <br />                                         food liquid contaminated T. cruzi, generally associated massive <br />                                         parasitic infestation, resulting severe acute clinical presentation high mortality <br />                                         [5,6]. <br />  <br />                                         Clinically, disease characterized phases: acute, indeterminate chronic. <br />                                         During acute phase, T. cruzi easily detected blood. Then parasitemia <span id='am-96' about='obo:NCBITaxon_376232' typeof='obo:NCBITaxon_34667 obo:NCBITaxon_79514 owl:Thing obo:NCBITaxon_33340 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_71528 obo:NCBITaxon_41084 obo:NCBITaxon_33154 obo:NCBITaxon_192380 obo:NCBITaxon_33317 obo:NCBITaxon_2759 obo:NCBITaxon_6072 obo:NCBITaxon_6960 obo:NCBITaxon_33208 obo:NCBITaxon_197562 obo:NCBITaxon_85512 obo:NCBITaxon_197563 obo:NCBITaxon_41088 obo:NCBITaxon_6656 obo:NCBITaxon_7496 obo:NCBITaxon_1206794 obo:NCBITaxon_88770 obo:NCBITaxon_33392 obo:NCBITaxon_50557 obo:NCBITaxon_7041'><span id='am-97'  ></span><span id='am-98' property="rdfs:label" content="Goes" datatype="xsd:string"></span><span id='am-99' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-100' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>goes</span> <br />                                         down, making diagnostics complicated. The severity acute phase, which <br />                                         lasts 4 &#8211; 8 weeks, depends different factors, parasite load strain, <br />                                         patient immune response varies mild unrecognized flu-like illness to <br />                                         symptoms hepatosplenomegaly, meningoencephalitis myocarditis, fatality rate being <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         &lt; 5%. The indeterminate phase generally asymptomatic comprises period may <br />                                         10 &#8211; 20 years. Then, ~ 30% infected patients develop chronic form the <br />                                         disease, cardiac (arrhythmias, congestive heart failure, cardiac enlargement, <br />                                         thromboembolism sudden cardiac death), digestive (megaoesophagus mega colon) <br />                                         cardiodigestive [1,7&#8211;9]. About 60% patients chronic Chagas disease die 7 months <br />                                         2 years onset symptoms [10]. The risk disease activation sharply <br />                                         increases immunodeficient patients (immunosuppressant therapies [11], HIV coinfections <br />                                         [12]). <br />  <br />                                         Chagas disease afflicting humans South America 9,000 years, 41% <br />                                         prevalence rate tissue specimens human mummies reported [13]. Sadly <br />                                         enough, infection remains endemic 18 countries, represents the <br />                                         leading causes morbidity, long-term disability mortality [14]. In late 1970s, 20% <br />                                         Bolivian population estimated infected T. cruzi, rural areas <br />                                         provided prevalence rates 40 80% [15]. Over past decades, however, WHO <br />                                         statistics certainly improved. While 1990 WHO reported 18 million infected, <br />                                         700,000 new cases 50,000 deaths year South Central America, 2000 the <br />                                         corresponding numbers declined 200,000 new cases 21,000 deaths year [16] and <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         ~ 10 million infected reported 2010 [17]. This improvement largely <br />                                         extensive vector donor blood bank control programs endemic areas [1,6], <br />                                         change prevailing view nature disease. <br />  <br />                                         For decades drug development Chagas basically halted &#8216;outstanding <br />                                         influence&#8217; [2] so-called neurogenic postulate followed autoimmune hypothesis, of <br />                                         essentially based <span id='am-140' about='obo:NCBITaxon_1369087' typeof='obo:NCBITaxon_37567 owl:Thing obo:NCBITaxon_33340 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_85604 obo:NCBITaxon_104431 obo:NCBITaxon_33154 obo:NCBITaxon_37570 obo:NCBITaxon_41191 obo:NCBITaxon_33317 obo:NCBITaxon_2759 obo:NCBITaxon_6072 obo:NCBITaxon_6960 obo:NCBITaxon_33208 obo:NCBITaxon_41196 obo:NCBITaxon_197562 obo:NCBITaxon_85512 obo:NCBITaxon_197563 obo:NCBITaxon_95182 obo:NCBITaxon_41197 obo:NCBITaxon_6656 obo:NCBITaxon_7496 obo:NCBITaxon_7088 obo:NCBITaxon_1206794 obo:NCBITaxon_88770 obo:NCBITaxon_7100 obo:NCBITaxon_33392 obo:NCBITaxon_50557'><span id='am-141' property="rdfs:label" content="Data" datatype="xsd:string"></span><span id='am-142' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-143' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-144'  ></span>data</span> obtained insufficient sensitivity the <br />                                         techniques employed stated chronic form Chagas considered as <br />                                         infectious disease inflammatory disease/imbalanced immune response. <br />                                         Consequently, specific antiparasitic treatment declared irrelevant abandoned, and <br />                                         treatment aimed mitigate symptoms (such antiarrhythmic drugs, <br />                                         pacemakers heart transplantation [1]) remained provided. For example, according to <br />                                         autoimmune hypothesis, parasite triggers autoimmune response some <br />                                         hosts, persistence does play role disease pathogenesis. Therefore, <br />  <br />  <br />                                        Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01. <br />                             Lepesheva                                                                                               Page 3 <br />  <br />  <br />                                         successful antiparasitic treatment lead improvement clinical <br />                                         outcome [2,18]. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         Fortunately, however, recent studies, using sensitive methods demonstrated clear <br />                                         correlation inflammatory processes presence parasite [19], thus <br />                                         supporting alternative opinion eradication T. cruzi infected patients a <br />                                         prerequisite cure disease [20&#8211;23], etc.). The prevailing view begun change; <br />                                         nevertheless, damage done. The disease acquired status incurable, and <br />                                         consequently, highly neglected, turn delayed development i) <br />                                         specific etiological treatment, ii) efficient diagnostics iii) cure evaluation criteria [9]. <br />                                         Within past years, certain progress achieved fields. This article <br />                                         concentrate aspect: specific antiparasitic chemotherapy, mostly <br />                                         focusing CYP51 inhibitors. <br />  <br />                                         Other modern strategies develop antitrypanosomal treatment Chagas disease include <br />                                         phenotypic (whole organism) screening libraries biologically active small molecules <br />                                         new chemotypes trypanocidal activity, fast vivo screening compounds <br />                                         identified vitro, mining T. cruzi genome new drug targets; searching efficient <br />                                         inhibitors potential targets (proteins/DNA) confirmed essential the <br />                                         parasite survival. These approaches highly promising eventually lead to <br />                                         pioneering discoveries. But lack knowledge molecular target/mechanism the <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         compounds identified phenotypic screening make lead optimization process <br />                                         highly challenging. On hand, target selection minefield potential issues, <br />                                         target essential, druggable available <br />                                         assay vitro. Thus, process certainly time requires significant financial <br />                                         investments. Pharmaceutical companies, however, remain reluctant invest resources the <br />                                         development antichagasic drugs, especially lack assurances they <br />                                         make return investment. <br />  <br />                                         In meantime, Chagas disease severe global medical challenge, mainly due <br />                                         human/vector migration [24], lack awareness diagnostics in <br />                                         nonendemic areas [25,26]. Some estimates indicate 1 million cases of <br />                                         Chagas disease United States [27], 267,000 cases Texas [28]. <br />                                         The majority infected reported immigrants Latin America [29]. Yet it <br />                                         known infected insects widely spread southern states the <br />                                         country, largely feeding wild animals (in 2007, 30% armadillos 38% of <br />                                         opossums Louisiana infected T. cruzi [27]), occasionally affecting <br />                                         domestic dogs (e.g., 537 confirmed canine cases Chagas disease 1993 <br />                                         2007 Texas [30]), humans [31,32]. Many cases autochthonous vector-borne <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         transmission United States presumed occur undetected, sustaining risk of <br />                                         infection blood organ donation mother child [29]. More 5,500 <br />                                         individuals infected T. cruzi reported Canada, &gt; 3000 Japan, &gt; 1500 in <br />                                         Australia [33] &gt; 80,000 Spain [34]. In Europe, recognized majority <br />                                         patients remain untreated, index undiagnosed cases 94 &#8211; 96% [26,35]. For <br />                                         millions infected, dreading onset worsening symptoms, by <br />                                         far greatest importance availability options immediate treatment. <br />  <br />                               2. Current clinical etiological treatment Chagas disease <br />                                         Currently, drugs available therapeutic use T. cruzi humans: <br />                                         nifurtimox benznidazole [29]. Both nitroheterocyclic compounds (Figure <br />                                         1A), discovered 1965 1971, respectively [36]. Nifurtimox 5-nitrofuran <br />                                         derivative; benznidazole 2-nitroimidazole derivative. As nitroheterocycles, they <br />  <br />  <br />                                        Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01. <br />                             Lepesheva                                                                                               Page 4 <br />  <br />  <br />                                         function prodrugs undergo activation nitro group the <br />                                         pathogen mediating cytotoxic effects, likely damage DNA other <br />                                         macromolecules [37&#8211;39]. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         Unfortunately, benznidazole nifurtimox variable efficiency different T. <br />                                         cruzi strains [40] considerable adverse effects, especially adults, which <br />                                         frequently result treatment discontinuation [9]. Particularly, 50 &#8211; 70% patients treated <br />                                         nifurtimox suffer gastrointestinal disorders, neurologic toxicity occurs to <br />                                         50% patients. Benznidazole better tolerated nifurtimox and, therefore, is <br />                                         recommended first-choice treatment [8], produce severe dermatitis <br />                                         bone marrow disorders [41]. <br />  <br />                                         Neither drug approved US Food Drug Administration (FDA), can <br />                                         potentially obtained special request Center Disease Control used <br />                                         investigational protocols [29]. According recommendations 2005 2007, <br />                                         antitrypanosomal treatment strongly advised cases acute, congenital and <br />                                         reactivated infection, children infection, patients 18 years age <br />                                         chronic disease. Drug treatment generally offered adults aged 19 &#8211; 50 <br />                                         years advanced Chagas heart disease, optional &gt; 50 years. There are <br />                                         debates drugs used late chronic stage, mainly to <br />                                         adverse effects difficulties cure assesment. Treatment failures still <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         widely reported. However, now, multiple reports indicating treatment <br />                                         benznidazole/nifurtimox prevent reverse development chronic <br />                                         symptoms disease [1,4,7,9,20,42]. More extended trials proposed [9]. <br />                                         Attempts improve drug properties altered formulations, etc. being <br />                                         undertaken [8]. Moreover, novo design broad testing safer nitroheterocycles, for <br />                                         example, 3-nitrotriazole amines (Figure 1A) currently supported Drugs for <br />                                         Neglected Disease initiative (DNDi) appears promising [43]. <br />  <br />                               3. Screening existing antifungal drugs <br />                                         Azole derivatives served successful antifungal drugs four <br />                                         decades [44&#8211;46]. They act blocking ergosterol biosynthesis <span id='am-12' about='obo:NCBITaxon_4751' typeof='obo:NCBITaxon_33154 owl:Thing obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_2759'><span id='am-13' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-14' property="oboInOwl:hasExactSynonym" content="fungi" datatype="xsd:string"></span><span id='am-15' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-16'  ></span><span id='am-17' property="oboInOwl:hasDbXref" content="PMID:11062127" datatype="xsd:string"></span><span id='am-18' property="rdfs:label" content="Fungi" datatype="xsd:string"></span><span id='am-19' property="oboInOwl:hasDbXref" content="PMID:12684019" datatype="xsd:string"></span><span id='am-20' property="oboInOwl:hasRelatedSynonym" content="fungi" datatype="xsd:string"></span>fungi</span> inhibition the <br />                                         cytochrome P450 enzyme, called sterol 14&#945;-demethylase (CYP51). CYP51 only <br />                                         essential sterol biosynthesis happened highly druggable. While the <br />                                         electronegative nitrogen azole heterocyclic ring forms coordination bond the <br />                                         catalytic heme iron, decreasing reduction potential, noncoordinated, hydrophobic <br />                                         portion azole-containing molecule forms multiple van der Waals contacts the <br />                                         amino acid residues inside hydrophobic substrate binding cavity enzyme, <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         preventing substrate binding metabolism. Together, Fe&#8211;N coordination and <br />                                         hydrophobic interactions apoprotein moiety ensure tight binding very <br />                                         strong, functionally irreversible inhibitory effect catalysis [47]. It known <br />                                         small azole derivatives, imidazole phenyl-imidazole, little influence on <br />                                         CYP51 activity; effects larger molecules strongly depend their <br />                                         composition [48]. It noteworthy antifungal azole drugs discovered <br />                                         empirically cellular studies, based antifungal effects produced screening. <br />                                         Their mechanism action proven sterol analysis (accumulation 14&#945;- <br />                                         methylated sterol precursors) [49]. Testing potencies CYP51 inhibitors not <br />                                         included drug discovery process because, highly hydrophobic <br />                                         membrane-bound proteins, fungal CYP51s difficult handle assay vitro. <br />                                         Absence structural information fungal CYP51 complicates drug <br />                                         development. As result, currently azoles approved clinical systemic <br />                                         use: ketoconazole, itraconazole, posaconazole, fluconazole voriconazole (Figure 1B). <br />  <br />  <br />                                        Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01. <br />                             Lepesheva                                                                                              Page 5 <br />  <br />  <br />                                         Some closely related compounds, ravuconazole, TAK-187 UR9825 <br />                                         (Figure 1B) trials/development. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         Similar fungi, T. cruzi completely dependent endogenously produced sterols <br />                                         (ergosterol 24-alkylated derivatives) [50] vital parasite membranes, <br />                                         cell division, growth development processes [47]. Therefore, <span id='am-60' about='obo:NCBITaxon_76236' typeof='owl:Thing obo:NCBITaxon_37567 obo:NCBITaxon_33340 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_30248 obo:NCBITaxon_131567 obo:NCBITaxon_85604 obo:NCBITaxon_104431 obo:NCBITaxon_33154 obo:NCBITaxon_33415 obo:NCBITaxon_33317 obo:NCBITaxon_41191 obo:NCBITaxon_2759 obo:NCBITaxon_6072 obo:NCBITaxon_6960 obo:NCBITaxon_37572 obo:NCBITaxon_304572 obo:NCBITaxon_33208 obo:NCBITaxon_85512 obo:NCBITaxon_197562 obo:NCBITaxon_41196 obo:NCBITaxon_197563 obo:NCBITaxon_41197 obo:NCBITaxon_6656 obo:NCBITaxon_7496 obo:NCBITaxon_7088 obo:NCBITaxon_1206794 obo:NCBITaxon_88770 obo:NCBITaxon_127218 obo:NCBITaxon_33392 obo:NCBITaxon_50557'><span id='am-61' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-62' property="rdfs:label" content="Idea" datatype="xsd:string"></span><span id='am-63' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-64'  ></span>idea</span> screening the <br />                                         existing antifungal agents potential drugs specific etiological treatment Chagas <br />                                         disease reasonable, especially market much <br />                                         safer benznidazole nifurtimox. <br />  <br />                                         The report showing topical antifungal drugs, miconazole econazole, inhibit <br />                                         growth T. cruzi (Tulahuen strain) published 1981 [51]. In 1984, antiparasitic effect <br />                                         ketoconazole reported vivo mouse models Chagas disease induced four <br />                                         different strains parasite [52], including Y strain sensitive to <br />                                         nitroderivatives [40]. In experiments, 60 mg/kg/bid dosage given 7 days <br />                                         ketoconazole protected mice death, treatment started parasitemia <br />                                         onset. Parasitological cure achieved, presumably short (4 h) life time of <br />                                         drug mouse plasma. Because incidence effects humans treated with <br />                                         ketoconazole years known low, authors suggested drug <br />                                         tested therapeutic agent Chagas disease [52]. However, testing of <br />                                         ketoconazole humans demonstrated able eradicate parasitemia from <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         treated chronic chagasic patients [53]. A years later, itraconazole, triazole <br />                                         derivative ketoconazole display better results. Treatment infected mice <br />                                         120 mg itraconazole/kg/day 7 &#8211; 9 weeks resulted parasitological cure as <br />                                         determined negative hemocultures subinoculations, negative serology T. cruzi, <br />                                         absence parasites histological sections following completion therapy [54]. <br />                                         Treatment humans chronic Chagas disease itraconazole produced <br />                                         parasitological cure 53% normalization electrocardiogram (ECG) 48% of <br />                                         patients (four years follow-up period) [55]. Further, 20 years&#8217; follow-up, 54.3% the <br />                                         patients negative parasitological tests used, 60% cases had <br />                                         normal ECG traces [56]. Fluconazole did cure mice treatment 200 mg/kg <br />                                         daily dosage 30 days [57], fact agreement relatively weak <br />                                         inhibitory potency T. cruzi CYP51 inhibitor vitro [58,59]. Its close-derivative <br />                                         voriconazole, however, recently reported reveal suppressive effect a <br />                                         mouse model (75% survival rate 40 mg/kg/day dosage administered 30 days; <br />                                         Tulahuen strain T. cruzi) [60]. <br />  <br />                                         Several antifungal drug candidates, TAK-187, UR9825 [61,62], strong <br />                                         potential treatment Chagas disease. Most potent them, D0870, cured short- <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         long-term experimental Chagas disease mice [63], unfortunately failed clinical <br />                                         trials antifungal drug cardiotoxicity (inhibitory effect hERG channel <br />                                         causing QTc prolongation [64]). Finally, 2012, posaconazole (the derivative of <br />                                         itraconazole) ravuconazole (the derivative voriconazole) entered clinical trials for <br />                                         Chagas disease Spain, Bolivia <span id='am-129' about='obo:NCBITaxon_260511' typeof='owl:Thing obo:NCBITaxon_33511 obo:NCBITaxon_186623 obo:NCBITaxon_41705 obo:NCBITaxon_33208 obo:NCBITaxon_33213 obo:NCBITaxon_7711 obo:NCBITaxon_1 obo:NCBITaxon_1489388 obo:NCBITaxon_131567 obo:NCBITaxon_186625 obo:NCBITaxon_117570 obo:NCBITaxon_89593 obo:NCBITaxon_7742 obo:NCBITaxon_117571 obo:NCBITaxon_1489341 obo:NCBITaxon_33154 obo:NCBITaxon_7776 obo:NCBITaxon_170194 obo:NCBITaxon_134613 obo:NCBITaxon_7898 obo:NCBITaxon_32443 obo:NCBITaxon_41665 obo:NCBITaxon_2759 obo:NCBITaxon_6072'><span id='am-130' property="oboInOwl:hasRelatedSynonym" content="Argentina Linnaeus, 1758" datatype="xsd:string"></span><span id='am-131' property="rdfs:label" content="Argentina" datatype="xsd:string"></span><span id='am-132'  ></span><span id='am-133' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-134' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span>Argentina</span>. <br />  <br />                                         Undoubtedly, successful repurposing clinical antifungal drugs Chagas disease would <br />                                         cost-efficient way provide immediate treatment needed urgently. <br />                                         However, second-use application certain limitations. Thus, ravuconazole requires <br />                                         optimization produces suppressive effect animal models Chagas <br />                                         disease, probably largely pharmacokinetics, particularly low bioavailability <br />                                         [65,66]. Posaconazole, extensively studied antichagasic drug candidate by <br />                                         J. A. Urbina&#8217;s team proved highly potent vivo infection caused <br />                                         multiple, including nitroderivative-resistant strains T. cruzi [66], is <br />  <br />  <br />                                        Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01. <br />                             Lepesheva                                                                                               Page 6 <br />  <br />  <br />                                         unfortunately highly expensive complex low-yielding synthetic scheme [67] <br />                                         issues bioavailability. Although posaconazole cured chronic chagasic <br />                                         patient [68], hospital patient cost 8,000 euro [69], authors reporting the <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         success drug indicate &#8216;its current cost high widespread use in <br />                                         endemic countries&#8217; [68]. Other agents mechanism action lower <br />                                         potential cost needed [69]. <br />  <br />                               4. Experimental inhibitors T. cruzi CYP51 CYP51-structure-based <br />                               drug design development <br />                                         Contrary fungal CYP51s, sterol 14&#945;-demethyases <span id='am-46' about='obo:NCBITaxon_5654' typeof='owl:Thing obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_33682 obo:NCBITaxon_2759 obo:NCBITaxon_5653'><span id='am-47'  ></span><span id='am-48' property="rdfs:label" content="Trypanosomatidae" datatype="xsd:string"></span><span id='am-49' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-50' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span>Trypanosomatidae</span> <br />                                         pathogens, T. cruzi, T. brucei <span id='am-21' about='obo:NCBITaxon_5671' typeof='owl:Thing obo:NCBITaxon_38574 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_5658 obo:NCBITaxon_33682 obo:NCBITaxon_1286322 obo:NCBITaxon_5654 obo:NCBITaxon_2759 obo:NCBITaxon_38568 obo:NCBITaxon_5653'><span id='am-22' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-23'  ></span><span id='am-24' property="oboInOwl:hasAlternativeId" content="NCBITaxon:5662" datatype="xsd:string"></span><span id='am-25' property="rdfs:label" content="Leishmania infantum" datatype="xsd:string"></span><span id='am-26' property="oboInOwl:hasRelatedSynonym" content="Leishmania (Leishmania) infantum" datatype="xsd:string"></span><span id='am-27' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-28' property="oboInOwl:hasRelatedSynonym" content="Leishmania donovani infantum" datatype="xsd:string"></span>Leishmania infantum</span> (25% average amino acid sequence <br />                                         identity fungal orthologs) characterized biochemically structurally <br />                                         [58,59,70&#8211;72]. Studies inhibition activity reconstituted catalytic reaction in <br />                                         vitro revealed susceptibilities protozoan CYP51s antifungal drugs differ <br />                                         significantly fungal orthologs, led identification novel <br />                                         experimental inhibitory scaffolds (Figure 1C) [58,73&#8211;75], including indomethacin amid <br />                                         derivatives (INDO-pyridine scaffold) [75], substrate analog 14&#945;- <br />                                         methylenecyclopropyl-24,25-dihydrolanosterol (MCP) [74] carboxamide containing &#946;- <br />                                         phenyl imidazoles (VNI scaffold) [58]. INDO-pyridine derivatives interesting of <br />                                         potential dual action vivo: nonazole heme binding CYP51 inhibitors COX2 <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         inhibitors (anti-inflammatory effect). MCP example effective mechanism- <br />                                         based CYP51 inhibitor acts T. cruzi CYP51 selective suicide substrate. Testing of <br />                                         effects animal models Chagas disease currently progress, VNI has <br />                                         recently proven able cure, 100% cure rate 100% survival, the <br />                                         acute chronic forms Chagas disease mice [76]. Nontoxic, orally bioavailable, with <br />                                         favorable pharmacokinetics, mutagenicity influence hERG channel, easy to <br />                                         synthesize modify, VNI excellent drug candidate, clearly deserving broader <br />                                         attention accelerate progress clinical trials. <br />  <br />                                         CYP51 structural studies explained potencies VNI T. cruzi CYP51 <br />                                         inhibitors [70,77,78] uncovered molecular basis CYP51 exceptional <br />                                         druggability outlined directions undertaken rationally design better <br />                                         drugs. First foremost, contrary many, particularly human drug-metabolizing CYPs, <br />                                         enormous substrate promiscuity display high structural plasticity, <br />                                         CYP51s structure, especially substrate binding cavity, highly rigid [78]. This <br />                                         rigidity essential conserved CYP51 catalytic function, <span id='am-88' about='obo:NCBITaxon_order' typeof='owl:Thing NCBITaxon:_taxonomic_rank'><span id='am-89' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-90' property="rdfs:label" content="order" datatype="xsd:string"></span>order</span> preserve <br />                                         enzyme&#8217;s strict substrate specificity rare P450s three-step stereospecific <br />                                         reaction. During CYP51 reaction, sterol molecule maintained proper <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         catalytic position cytochrome P450 monooxygenation cycles 14&#945;- <br />                                         methyl group successively converted 14&#945;-alcohol, 14&#945;-aldehyde derivative <br />                                         finally C&#8211;C bond cleaved release 14&#945;-demethylated product and <br />                                         formic acid [47]. As result rigidity, ligand accommodated inside the <br />                                         enzyme binding cavity, best topological fit defining tightest binding and, <br />                                         accordingly, strongest inhibitory potency (Figure 2A). Second, substrate access <br />                                         channel CYP51 structures, ligand-free bound different ligands, remains <br />                                         open defined (Figure 2B), bordered helices A&#8242;, F&#8243; tip <span id='am-6' about='obo:NCBITaxon_3554' typeof='owl:Thing obo:NCBITaxon_78536 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_3398 obo:NCBITaxon_1437183 obo:NCBITaxon_33090 obo:NCBITaxon_3563 obo:NCBITaxon_91827 obo:NCBITaxon_71240 obo:NCBITaxon_131221 obo:NCBITaxon_58024 obo:NCBITaxon_1437201 obo:NCBITaxon_58023 obo:NCBITaxon_3524 obo:NCBITaxon_2759 obo:NCBITaxon_35493 obo:NCBITaxon_3193'><span id='am-7'  ></span><span id='am-8' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-9' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-10' property="rdfs:label" content="Beta" datatype="xsd:string"></span><span id='am-11' property="oboInOwl:hasRelatedSynonym" content="Beta L. 1753" datatype="xsd:string"></span>beta</span> 4 <br />                                         hairpin (these secondary structural elements enlarged marked Figure 2C). Finally, <br />                                         CYP51 substrate binding cavity extends deeper inside P450 molecule other <br />                                         CYPs, reaching <span id='am-65' about='obo:NCBITaxon_6534' typeof='owl:Thing obo:NCBITaxon_33208 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_87862 obo:NCBITaxon_131567 obo:NCBITaxon_6533 obo:NCBITaxon_6527 obo:NCBITaxon_33154 obo:NCBITaxon_1206795 obo:NCBITaxon_216305 obo:NCBITaxon_216366 obo:NCBITaxon_216307 obo:NCBITaxon_977775 obo:NCBITaxon_6447 obo:NCBITaxon_33317 obo:NCBITaxon_6448 obo:NCBITaxon_2759 obo:NCBITaxon_120490 obo:NCBITaxon_6072'><span id='am-66'  ></span><span id='am-67' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-68' property="rdfs:label" content="Helix" datatype="xsd:string"></span><span id='am-69' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>helix</span> C N-terminal portion helix I (Figure 2C). <br />  <br />                                         Using VNI scaffold example, I outline understanding three <br />                                         major CYP51 structural features rationally used accelerate drug development <br />  <br />                                        Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01. <br />                             Lepesheva                                                                                              Page 7 <br />  <br />  <br />                                         process. VNI CYP51 binding cavity oriented similar posaconazole (Figure 2A). <br />                                         The imidazole ring nitrogen (N3) coordinates heme iron, 2,4-dichlorinated &#946;-phenyl <br />                                         ring projected deepest portion enzyme substrate binding cavity, 3- <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         ring linear polycycle positioned substrate access channel connected the <br />                                         rest inhibitor molecule carboxamide fragment (Figure 2E). The carbonyl oxygen <br />                                         fragment forms hydrogen bond catalytic water molecule, connecting <br />                                         inhibitor CYP51 I-helix disrupting proton delivery route enzyme. <br />                                         The amide nitrogen fragment forms hydrogen bond OH group Y103, <br />                                         repositioning chain functionally essential residue, OH group in <br />                                         enzymatically active CYP51 enzymes provides support heme H-bonded <br />                                         porphyrin ring D propionate [71]. Based previous experience, location the <br />                                         phenyl ring &#946;-position relative azole ring presence/position the <br />                                         Cl atoms ring essential potency scaffold [58], replacement of <br />                                         chlorine atom fluorine replacement imidazole ring triazole <br />                                         ring (examples shown [79]) worsens pharmacokinetics (Villalta Lepesheva, <br />                                         unpublished). Thus central core scaffold, including imidazole ring, &#946;- <br />                                         phenyl ring, carboxamide fragment preserved. <br />  <br />                                         Other portions molecule potentially derivatized increase the <br />                                         potency enhance drug-like properties resulting compounds. Modifications be <br />                                         performed regions (Figure 2C F), molecule (as long it <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         complies Lipinski rules/ADME considerations) separately, aim produce <br />                                         alternative drug candidates; advantageous case acquired <br />                                         resistance. Extension VNI long arm (Figure 2C) mimic surface-binding sub- <br />                                         site, seen access channel entrance T. cruzi CYP51 co-structure <br />                                         posaconazole [3k1o] [70]. Filling deepest portion CYP51 binding cavity <br />                                         (Figure 2F) appears especially promising i) molecules smaller than <br />                                         VNI (VNF [70] later NEE [77]) accommodated (Figure 2A) proven to <br />                                         highly potent T. cruzi CYP51 inhibitors; ii) portion cavity is <br />                                         CYP51-specific, potentially mean substantial decrease influence other <br />                                         human CYPs, example, observed addition aromatic ring the <br />                                         &#946;-phenyl ring VNI: modification resulted &gt; 8-fold increase IC50 CYP3A4 <br />                                         inhibition [79]. <br />  <br />                                         Weaker influence human CYPs certainly desirable, importance for <br />                                         drugs aimed infectious diseases (especially poor people unlikely to <br />                                         permanently use large number additional medications) exaggerated: Drug- <br />                                         metabolizing CYPs essential, inducible activities being <br />                                         restored soon administration drug stopped [80]. Temporary inhibition of <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         human CYP51 unlikely real problem, humans consume cholesterol <br />                                         diet, inhibitors human CYP51 considered potential <br />                                         cholesterol-lowering drugs, studies abandoned, mainly high <br />                                         potency statins, drugs block sterol biosynthesis upstream CYP51 reaction <br />                                         [81]. <br />  <br />                                         High heterogeneity T. cruzi population reason development of <br />                                         CYP51 inhibitors helpful. More 70 different strains parasite <br />                                         (www.dbbm.fiocruz.br/TcruziDB/strain.html, 01/02/2013), joined six <br />                                         major groups (TcI &#8211; TcVI), vary broadly sensitivities clinical nitroheterocyclyc <br />                                         drugs benznidazole nifurtimox [40] and, apparently, antifungal azoles well, <br />                                         including D0870 posaconazole [82,83]. The CYP51 gene sequences different T. <br />                                         cruzi strains revealed surprising variability: example, CYP51s Colombiana and <br />                                         Sylvio (TcI group) 8 6 amino acid differences CYP51 Tulahuen (TcVI) <br />  <br />  <br />                                        Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01. <br />                             Lepesheva                                                                                                Page 8 <br />  <br />  <br />                                         [84]. Expression genes currently progress hopefully provide an <br />                                         explanation altered sensitivities T. cruzi strains azole inhibitors. Given that <br />                                         CYP51 regarded housekeeping gene (e.g., CYP51 human differs the <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         orthologs <span id='am-73' about='obo:NCBITaxon_9539' typeof='owl:Thing obo:NCBITaxon_9528 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_9526 obo:NCBITaxon_32523 obo:NCBITaxon_9527 obo:NCBITaxon_131567 obo:NCBITaxon_32524 obo:NCBITaxon_117570 obo:NCBITaxon_32525 obo:NCBITaxon_89593 obo:NCBITaxon_7742 obo:NCBITaxon_117571 obo:NCBITaxon_33154 obo:NCBITaxon_1437010 obo:NCBITaxon_1338369 obo:NCBITaxon_40674 obo:NCBITaxon_8287 obo:NCBITaxon_2759 obo:NCBITaxon_314146 obo:NCBITaxon_6072 obo:NCBITaxon_33511 obo:NCBITaxon_33208 obo:NCBITaxon_7711 obo:NCBITaxon_314294 obo:NCBITaxon_314293 obo:NCBITaxon_376913 obo:NCBITaxon_7776 obo:NCBITaxon_9347 obo:NCBITaxon_9443'><span id='am-74' property="oboInOwl:hasExactSynonym" content="macaques" datatype="xsd:string"></span><span id='am-75' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-76' property="rdfs:label" content="Macaca" datatype="xsd:string"></span><span id='am-77'  ></span><span id='am-78' property="oboInOwl:hasExactSynonym" content="macaque" datatype="xsd:string"></span><span id='am-79' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span>macaca</span> dog 3 8 amino acid residues, respectively), finding <br />                                         agrees hypothesis different T. cruzi lineages evolutionarily very <br />                                         distant (diverged 88 million years ago [85]), implying sensitivity potential <br />                                         drug targets likely higher variability parasite strains. <br />  <br />                               5. Other potential drug targets <br />                                         Currently, CYP51 inhibitors advanced drug candidates etiological treatment <br />                                         Chagas disease [9,17,61]. Several enzymes involved sterol biosynthetic <br />                                         pathway potential serve possible future targets antitrypanosomal <br />                                         chemotherapy. The apparent examples HMG-CoA reductase, humans is <br />                                         clinical target statins, farnesyl diphosphate synthase, target bisphosphonates, <br />                                         squalene synthase, inhibited quinuclidine derivatives sterol 24- <br />                                         methyltransferase, inhibited azasterols [47]. So far, however, antiparasitic activity of <br />                                         inhibitors vivo reported used combination antifungal <br />                                         azoles, producing synergistic effect [61] suggesting blockage sterol <br />                                         biosynthesis different stages highly advantageous, Chagas disease <br />                                         treatment, sterol-dependent human pathogens, including fungi. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         Synergetic antiparasitic effect antiarrhythmic drug amiodaron posaconazole <br />                                         appears particularly interesting example, amiodaron, recently to <br />                                         inhibit lanosterol synthase, frequently used chronic cardiac Chagas disease <br />                                         patients [86]. This opens possibility combining drugs approved for <br />                                         clinical use. <br />  <br />                                         A number alternative potential targets metabolic pathways crucial for <br />                                         T. cruzi survival intracellular development reported, thiol-dependent <br />                                         redox metabolism (trypanothione reductase), glycolysis (glyceraldehyde-3-phosphate <br />                                         dehydrogenase); pentose phosphate pathway, purine salvage pathway nucleotide <br />                                         synthesis, cysteine proteases (cruzain) kinetoplastid DNA binders (aromatic diamidines) <br />                                         [87]. The success difficult predict, particularly lack centralized <br />                                         program perform standardized comparative evaluation. For example, <br />                                         kDNA binders receive publicity, highly attractive <br />                                         specific Kinetoplastid pathogens and, addition pronounced <br />                                         antiparasitic effects vivo, induce decrease cardiac inflammation [88]. In contrast, <br />                                         broadly advertized cruzain inhibitor K777 reported receiving Investigational <br />                                         New Drug status [69], apparently despite hepatotoxicity [61] suppressive <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         antiparasitic effect mice dogs. Thus, long uneasy path involving validation of <br />                                         druggability, lead optimization lies ahead alternative drug targets. Right now <br />                                         CYP51 inhibitors closer offering cure Chagas disease. <br />  <br />                               6. Conclusion <br />                                         Both screening design drugs treatment Chagas disease promising. <br />                                         Further, mutually beneficial. It lack effort coordination <br />                                         severely halts progress. Including promising drug candidates VNI its <br />                                         derivatives sphere of pharmaceutical company, foundation a <br />                                         partnership claim devoted success drug discovery neglected tropical <br />                                         diseases developed integrated strategy evaluating medicinal chemistry, <br />                                         safety, pharmacokinetics, pharmacodynamics, etc. [89]. highly helpful in <br />                                         advancing leading compounds clinical trials. <br />  <br />  <br />                                        Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01. <br />                             Lepesheva                                                                                               Page 9 <br />  <br />  <br />                                         It years follow-up results posaconazole/ravuconazole clinical trials <br />                                         available. In meantime, additional phenotypic high throughput <br />                                         screenings (HTS) completed, bringing new hits new hopes. In noteworthy that <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         statements (which appear reports HTS-conducting teams) about <br />                                         excluding libraries hits &#8216;look like CYP51 inhibitors&#8217; sound <br />                                         especially reasonable. On contrary, hits thoroughly studied have <br />                                         higher probability success vs. attrition. In fact, optimization HTS hit (plant <br />                                         antifungal agent fenarimol) DNDi [90] led development highly <br />                                         promising potent nonazole drug candidates, costructures T. cruzi CYP51 <br />                                         (PDB ID 3zg2 3zg3) [91] facilitate finishing steps drug discovery <br />                                         process. Impartial comprehensive comparative preclinical testing advanced <br />                                         experimental CYP51 inhibitors appears good way offer safer affordable <br />                                         specific treatment Chagas disease outcomes clinical trials posaconazole <br />                                         ravuconazole clearer. <br />  <br />                               7. Expert opinion <br />                                         The major advance field certainly growing appreciation Chagas disease a <br />                                         persistent parasitic infection treated infectious disease requires <br />                                         parasitological cure, regardless stage, order prevent development clinical <br />                                         symptoms. Also, highly encouraging information efficacy current, although <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         optimal largely underutilized, antiparasitic drugs achieving cure, reducing the <br />                                         disease severity reversing chronic clinical symptoms killing parasite. The <br />                                         major weaknesses appear result long-term neglect gross underfunding. They <br />                                         include lack easily available reliable diagnostic procedures, shortages drug <br />                                         availability and, important, absence unanimous opinion criteria cure <br />                                         (e.g., serological tests used main assessment cure, long-lasting immune <br />                                         memory requires lengthy follow-up periods order indicate treatment worked). <br />                                         Development standardized sensitive quantitative PCR analyses protocols conduct <br />                                         preclinical animal studies allow reliable comparison new drug efficacies <br />                                         promising. <br />  <br />                                         The fact doctors recommended prescribe specific treatment Chagas <br />                                         disease encouraging, infected patients, search new, <br />                                         better safer drugs. Positive results eventually overcome low impetus now <br />                                         based lack belief drugs widely used proven efficacious. <br />                                         As detailed above, availability T. cruzi CYP51 structure makes structure-based <br />                                         rational lead optimization quite straightforward, multidisciplinary approach <br />                                         involving chemistry, biochemistry, structural cellular biology, pharmacology and <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         toxicology, comprehensive testing best drug candidates preformed a <br />                                         centralized unbiased organization required. Also, better knowledge biology and <br />                                         genetics various T. cruzi strains, eventually distinguished as <br />                                         different species, needed. As now, infections caused drug-resistant <br />                                         strains parasite, Colombiana, combination therapy include CYP51 <br />                                         inhibitors potent multiplying intracellular amastigotes than <br />                                         trypomastigotes [58,76] nitroderivatives seriously considered. This <br />                                         allow decrease dosage of, example, benznidazole alleviation of <br />                                         side-effects. <br />  <br />                                         Because organizations, including DNDi, formed invest into <br />                                         screenings programs drug discovery implementations [89], doubt <br />                                         future directions involve high throughput searches new active compounds of <br />                                         alternative mechanisms action mining T. cruzi genome novel potential <br />  <br />  <br />                                        Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01. <br />                             Lepesheva                                                                                                    Page 10 <br />  <br />  <br />                                         alternative drug targets. The efforts eventually lead important discoveries, <br />                                         advancing basic knowledge antimicrobial chemotherapy. New sets potent drugs <br />                                         supported efficient vector control programs hopefully work the <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         devastating disease eliminated. <br />  <br />                               Bibliography <br />                                         Papers special note highlighted (&#8226;) considerable <br />                                         (&#8226;&#8226;) readers. <br />  <br />                                         1&#8226;. Rassi A Jr, Rassi A, Marin-Neto JA. Chagas disease. Lancet. 2012; 375:1388&#8211;402. The paper <br />                                               provides interesting update current status Chagas disease. [PubMed: 20399979] <br />                                         2. Higuchi, MdL; Benvenuti, LA.; Martins Reis, M., et al. Pathophysiology heart Chagas&#8217; <br />                                            disease: current status new developments. Cardiovasc Res. 2003; 60:96&#8211;107. [PubMed: <br />                                            14522411] <br />                                         3. Tanowitz HB, Kirchhoff LV, Simon D, et al. Chagas&#8217; disease. Clin Microbiol Rev. 1992; 5:400&#8211;19. <br />                                            [PubMed: 1423218] <br />                                         4. Pinto Dias JC. The treatment Chagas disease (South American trypanosomiasis). Ann Intern <br />                                            Med. 2006; 144:772&#8211;4. [PubMed: 16702594] <br />                                         5. Pereira KS, Schmidt FL, Guaraldo AM, et al. Chagas&#8217; disease foodborne illness. J Food Prot. <br />                                            2009; 72:441&#8211;6. [PubMed: 19350996] <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         6. Coura JR, Borges-Pereira J. Chagas disease: known improved: a <br />                                            systemic review. Rev Soc Bras Med Trop. 2012; 45:286&#8211;96. [PubMed: 22760123] <br />                                         7. Sosa-Estani S, Segura EL. Etiological treatment patients infected Trypanosoma cruzi: <br />                                            experiences Argentina. Curr Opin Infect Dis. 2006; 6:583&#8211;7. [PubMed: 17075335] <br />                                         8. Salomon CJ. First century chagas&#8217; disease: overview novel approaches nifurtimox and <br />                                            benznidazole delivery systems. J Pharm Sci. 2012; 101:888&#8211;94. [PubMed: 22161779] <br />                                         9&#8226;. Bern C. Antitrypanosomal therapy chronic Chagas&#8217; disease. N Engl J Med. 2011; 364:2527&#8211;34. <br />                                               The paper summarized information current diagnostics clinical etiological <br />                                               treatment Chagas disease. [PubMed: 21714649] <br />                                         10. Prata A. Chagas&#8217; disease. Infect Dis Clin North Am. 1994; 8:61&#8211;76. [PubMed: 8021449] <br />                                         11. Altclas J, Sinagra A, Dictar M, et al. Chagas disease bone marrow transplantation: approach <br />                                             preemptive therapy. Bone Marrow Transplant. 2005; 36:123&#8211;9. [PubMed: 15908978] <br />                                         12. Sartori AMC, Ibrahim KY, Nunes, et al. Manifestations Chagas disease (American <br />                                             trypanosomiasis) patients HIV/AIDS. Ann Trop Med Parasitol. 2007; 101:31&#8211;50. <br />                                             [PubMed: 17244408] <br />                                         13. Aufderheide AC, Salo W, Madden M, et al. A 9,000-year record Chagas&#8217; disease. Proc Natl <br />                                             Acad Sci USA. 2004; 101:2034&#8211;9. [PubMed: 14766963] <br />                                         14&#8226;. Bustamante JM, Tarleton RL. Methodological advances drug discovery Chagas disease. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                               Expert Opin Drug Discov. 2011; 6:653&#8211;61. The review outlines new approaches fast vivo <br />                                               screening new antitrypanosomal drug candidates. [PubMed: 21712965] <br />                                         15. Bastien, J. The kiss keath: Chagas&#8217; disease Americas. Univ. Utah Press; Salt Lake City: <br />                                             1998. <br />                                         16. WHO Technical Report Series No 905 Press Release. World Health Organization; Geneva: 2002. <br />                                             Second report WHO expert committee control Chagas disease; p. 85Available <br />                                             from: http://apps.who.int/bookorders/anglais/detart1.jsp?codlan=1&amp;codcol=10&amp;codcch=905# <br />                                         17. World Health Organization (WHO). Chagas disease: Control Elimination. UNDP/World Bank/ <br />                                             WHO; 2010. They post annual reports at: http://www.who.int/topics/chagas_disease/en/ <br />                                         18. Urbina JA. Parasitological cure Chagas disease: possible? Is relevant? Mem Inst Oswaldo <br />                                             Cruz. 1999; 94:349&#8211;55. [PubMed: 10677754] <br />                                         19&#8226;. Tarleton RL, Zhang L, Downs MO. &#8220;Autoimmune rejection&#65533;? neonatal heart transplants in <br />                                               experimental Chagas disease parasite-specific response infected host tissue. Proc Natl <br />                                               Acad Sci USA. 1997; 94:3932&#8211;7. This work proven chronic form Chagas should <br />                                               treated infectious disease. [PubMed: 9108082] <br />  <br />  <br />                                        Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01. <br />                             Lepesheva                                                                                                   Page 11 <br />  <br />  <br />                                         20. Viotti R, Vigliano C, Armenti H, et al. Treatment chronic Chagas&#8217; disease benznidazole: <br />                                             clinical serologic evolution patients long-term follow-up. Am Heart J. 1994; 127:151&#8211; <br />                                             62. [PubMed: 8273735] <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         21. Andrade SG, Stocker-Guerret S, Pimentel AS, et al. Reversibility cardiac fibrosis mice <br />                                             chronically infected Trypanosoma cruzi, specific chemotherapy. Mem Inst Oswaldo <br />                                             Cruz. 1991; 86:187&#8211;200. [PubMed: 1842413] <br />                                         22. Kaplan D, Ferrari I, Bergami PL, et al. Antibodies ribosomal P proteins Trypanosoma cruzi in <br />                                             Chagas disease possess functional autoreactivity heart tissue differ anti-P <br />                                             autoantibodies lupus. Proc Natl Acad Sci USA. 1997; 94:10301&#8211;6. [PubMed: 9294205] <br />                                         23. Docampo R, Schmu&#241;is GA. Sterol biosynthesis inhibitors: potential chemotherapeutics against <br />                                             chagas disease. Parasitol Today. 1997; 13:129&#8211;30. [PubMed: 15275097] <br />                                         24. Leslie M. Drug developers finally aim neglected disease. Science. 2011; 333:933&#8211;5. <br />                                             [PubMed: 21852468] <br />                                         25. Tarleton RL, Reithinger R, Urbina JA, et al. The challenges Chagas disease - grim outlook or <br />                                             glimmer hope? PLoS Med. 2007; 4:e332. [PubMed: 18162039] <br />                                         26. Klein N, Hurwitz I, Durvasula R. Globalization Chagas disease: growing concern in <br />                                             nonendemic countries. Epidemiol Res Int. 2012:1&#8211;13. Article ID 136793. <br />                                         27&#8226;. Hotez PJ. Neglected infections poverty United States America. PLoS Negl Trop Dis. <br />                                               2008; 2:e256. Globalization Ghagas disease problem (USA). [PubMed: 18575621] <br />                                         28&#8226;. Hanford EJ, Zhan FB, Lu Y, et al. Chagas disease Texas: recognizing significance and <br />                                               implications evidence literature. Soc Sci Med. 2007; 65:60&#8211;79. Globalization Ghagas <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                               disease problem (USA). [PubMed: 17434248] <br />                                         29. Bern C, Kjos S, Yabsley MJ, et al. Trypanosoma cruzi Chagas&#8217; disease United States. <br />                                             Clin Microbiol Rev. 2011; 24:655&#8211;81. [PubMed: 21976603] <br />                                         30. Esch KJ, Petersen CA. Transmission epidemiology zoonotic protozoal diseases of <br />                                             companion animals. Clin Microbiol Rev. 2013; 26:58&#8211;85. [PubMed: 23297259] <br />                                         31. Barry MA, Weatherhead JE, Hotez PJ, et al. Childhood parasitic infections endemic United <br />                                             States. Pediatr Clin North Am. 2013; 60:471&#8211;85. [PubMed: 23481112] <br />                                         32&#8226;. Barry MA, Bezek S, Serpa JA, et al. Neglected infections poverty Texas rest the <br />                                               United States: management treatment options. Clin Pharmacol Ther. 2012; 92:170&#8211;81. <br />                                               Globalization Ghagas disease problem (USA). [PubMed: 22760004] <br />                                         33. Coura JR, Vi&#241;as PA. Chagas disease: new worldwide challenge. Nature. 2010; 465:S6&#8211;7. <br />                                             [PubMed: 20571554] <br />                                         34. Schmunis GA, Yadon ZE. Chagas disease: Latin American health problem world <br />                                             health problem. Acta Trop. 2010; 115:14&#8211;21. [PubMed: 19932071] <br />                                         35&#8226;. Basile L, Jansa JM, Carlier Y, et al. Chagas disease European countries: challenge a <br />                                               surveillance system. Euro Surveill. 2011; 16:1&#8211;10. Globalization Ghagas disease problem <br />                                               (Europe). <br />                                         36. Mady C, Ianni BM, Souza JLJ. Benznidazole Chagas disease: old drug answer <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             old problem? Expert Opin Investig Drugs. 2008; 17:1427&#8211;33. <br />                                         37. Raether W, Hanel H. Nitroheterocyclic drugs broad spectrum activity. Parasitol Res. 2003; <br />                                             S1:S19&#8211;39. [PubMed: 12811546] <br />                                         38. Mejia AM, Hall BS, Taylor MC, et al. Benznidazole-resistance Trypanosoma cruzi readily <br />                                             acquired trait arise independently single population. J Infect Dis. 2012; 206:220&#8211;8. <br />                                             [PubMed: 22551809] <br />                                         39. Wilkinson SR, Taylor MC, Horn D, et al. A mechanism cross-resistance nifurtimox and <br />                                             benznidazole trypanosomes. Proc Natl Acad Sci USA. 2008; 105:5022&#8211;7. [PubMed: 18367671] <br />                                         40&#8226;. Filardi LS, Brener Z. Susceptibility natural resistance Trypanosoma cruzi strains drugs <br />                                               used clinically Chagas disease. Trans R Soc Trop Med Hyg. 1987; 81:755&#8211;9. First report <br />                                               showing drug susseptibility varyes significally different T. cruzi strains. [PubMed: <br />                                               3130683] <br />                                         41. Castro JA, Mecca MM, Bartel LC. Toxic effects drugs used treat Chagas&#8217; disease <br />                                             (American trypanosomiasis). Hum Exp Toxicol. 2006; 8:471&#8211;9. [PubMed: 16937919] <br />  <br />  <br />  <br />                                        Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01. <br />                             Lepesheva                                                                                                   Page 12 <br />  <br />  <br />                                         42. Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes treating chronic Chagas <br />                                             disease benznidazole versus treatment. A nonrandomized trial. Ann Intern Med. 2006; <br />                                             144:724&#8211;34. [PubMed: 16702588] <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         43. Papadopoulou MV, Trunz BB, Bloomer WD, et al. Novel 3-nitro-1H-1,2,4-triazole-based aliphatic <br />                                             aromatic amines anti-Chagasic agents. J Med Chem. 2011; 54:8214&#8211;23. [PubMed: <br />                                             22023653] <br />                                         44. Bennett JE. Chemotherapy systemic mycoses. N Engl J Med. 1974; 290:320&#8211;3. [PubMed: <br />                                             4588286] <br />                                         45. Maertens JA. History development azole derivatives. Clin Microbiol Infect. 2004; <br />                                             10:101&#8211;10. <br />                                         46. Ostrosky-Zeichner L, Casadevall A, Galgiani JN, et al. An insight antifungal pipeline: <br />                                             selected new molecules beyond. Nat Rev Drug Discov. 2010; 9:719&#8211;27. [PubMed: 20725094] <br />                                         47. Lepesheva GI, Villalta F, Waterman MR. Targeting Trypanosoma cruzi sterol 14&#945;-demethylase <br />                                             (CYP51). Adv Parasitol. 2011; 75:65&#8211;87. [PubMed: 21820552] <br />                                         48. Correia, MA.; Ortiz Montellano, PR. Inhibition cytochrome P450 enzymes. In: Ortiz de <br />                                             Montellano, PR., editor. Cytochrome P450: structure, mechanism, biochemistry. Plenum <br />                                             Publishing Corp; New York: 2005. p. 246-322. <br />                                         49. Vanden Bossche, H., editor. Mode action pyridine, pyrimidine azole antifungals. Ellis <br />                                             Horwood; Chichester: 1988. p. 79-119. <br />                                         50. Roberts CW, McLeod R, Rice DW, et al. Fatty acid sterol metabolism: potential antimicrobial <br />                                             targets apicomplexan trypanosomatid parasitic protozoa. Mol Biochem Parasitol. 2003; <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             126:129&#8211;42. [PubMed: 12615312] <br />                                         51&#8226;. Docampo R, Moreno SN, Turrens JF, et al. Biochemical ultrastructural alterations produced <br />                                               miconazole econazole Trypanosoma cruzi. Mol Biochem Parasitol. 1981; 3:169&#8211;80. <br />                                               First report antitrypanosomal activity antifungal azole. [PubMed: 6265775] <br />                                         52. McCabe RE, Remington JS, Araujo FG. Ketoconazole inhibition intracellular multiplication of <br />                                             Trypanosoma cruzi protection mice lethal infection organism. J Infect Dis. <br />                                             1984; 150:594&#8211;601. [PubMed: 6092485] <br />                                         53. Brener Z, Can&#231;ado JR, Galvao LM, et al. An experimental clinical assay ketoconazole in <br />                                             treatment Chagas disease. Mem Inst Oswaldo Cruz. 1993; 88:149&#8211;53. [PubMed: 8246750] <br />                                         54. McCabe RE, Remington JS, Araujo FG. In vitro vivo effects itraconazole against <br />                                             Trypanosoma cruzi. Am J Trop Med Hyg. 1986; 35:280&#8211;4. [PubMed: 3006529] <br />                                         55. Apt W, Aguilera X, Arribada A, et al. Treatment chronic Chagas&#8217; disease itraconazole and <br />                                             allopurinol. Am J Trop Med Hyg. 1998; 59:133&#8211;8. [PubMed: 9684641] <br />                                         56. Apt W, Arribada A, Zulantay I, et al. Treatment Chagas&#8217; disease itraconazole: <br />                                             electrocardiographic parasitological conditions 20 years follow-up. J Antimicrob <br />                                             Chemother. 2013; 68(9):2164&#8211;9. [PubMed: 23645584] <br />                                         57. Campos R, Amato Neto V, Moreira <span id='am-123' about='obo:NCBITaxon_152839' typeof='owl:Thing obo:NCBITaxon_78536 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_4447 obo:NCBITaxon_4747 obo:NCBITaxon_158359 obo:NCBITaxon_158331 obo:NCBITaxon_3398 obo:NCBITaxon_1437183 obo:NCBITaxon_33090 obo:NCBITaxon_158350 obo:NCBITaxon_73496 obo:NCBITaxon_131221 obo:NCBITaxon_58024 obo:NCBITaxon_58023 obo:NCBITaxon_2759 obo:NCBITaxon_35493 obo:NCBITaxon_1437197 obo:NCBITaxon_3193'><span id='am-124' property="oboInOwl:hasRelatedSynonym" content="Aa Rchb.f." datatype="xsd:string"></span><span id='am-125'  ></span><span id='am-126' property="rdfs:label" content="Aa" datatype="xsd:string"></span><span id='am-127' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-128' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>AA</span>, et al. Evaluation therapeutic activity fluconazole <br />                                             acute experimental infection caused Trypanosoma cruzi. Rev Hosp Clin Fac Med Sao Paulo. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             1992; 47:174&#8211;5. [PubMed: 1340597] <br />                                         58. Lepesheva GI, Ott RD, Hargrove TY, et al. Sterol 14 alpha-demethylase potential target for <br />                                             antitrypanosomal therapy: enzyme inhibition parasite cell growth. Chem Biol. 2007; 14:1283&#8211; <br />                                             93. [PubMed: 18022567] <br />                                         59. Lepesheva GI, Zaitseva NG, <span id='am-135' about='obo:NCBITaxon_203327' typeof='owl:Thing obo:NCBITaxon_186623 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_186625 obo:NCBITaxon_117570 obo:NCBITaxon_7742 obo:NCBITaxon_89593 obo:NCBITaxon_117571 obo:NCBITaxon_123369 obo:NCBITaxon_33154 obo:NCBITaxon_123367 obo:NCBITaxon_123368 obo:NCBITaxon_123365 obo:NCBITaxon_123366 obo:NCBITaxon_8220 obo:NCBITaxon_1489872 obo:NCBITaxon_2759 obo:NCBITaxon_8219 obo:NCBITaxon_6072 obo:NCBITaxon_33511 obo:NCBITaxon_33208 obo:NCBITaxon_7711 obo:NCBITaxon_1489388 obo:NCBITaxon_1489875 obo:NCBITaxon_1489878 obo:NCBITaxon_1489341 obo:NCBITaxon_7776 obo:NCBITaxon_497223 obo:NCBITaxon_7898 obo:NCBITaxon_32443 obo:NCBITaxon_41665'><span id='am-136' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-137' property="rdfs:label" content="Nes" datatype="xsd:string"></span><span id='am-138' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-139'  ></span>Nes</span> WD, et al. CYP51 Trypanosoma cruzi: phyla-specific <br />                                             residue B&#8217; helix defines substrate preferences sterol 14alpha-demethylase. J Biol Chem. <br />                                             2006; 281:3577&#8211;85. [PubMed: 16321980] <br />                                         60. Gulin JEN, Eagleson MA, Postan M, et al. Efficacy voriconazole murine model acute <br />                                             Trypanosoma cruzi infection. J Antimicrob Chemother. 2013; 68:888&#8211;94. [PubMed: 23212113] <br />                                         61. Urbina JA. New insights Chagas&#8217; disease treatment. Drug Fut. 2010; 35:409&#8211;19. <br />                                         62. Urbina JA. Specific chemotherapy Chagas disease: relevance, current limitations new <br />                                             approaches. Acta Trop. 2010; 115:55&#8211;68. [PubMed: 19900395] <br />                                         63. Urbina JA, Payares G, <span id='am-91' about='obo:NCBITaxon_356573' typeof='owl:Thing obo:NCBITaxon_33208 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_354335 obo:NCBITaxon_131567 obo:NCBITaxon_6820 obo:NCBITaxon_44327 obo:NCBITaxon_197562 obo:NCBITaxon_197563 obo:NCBITaxon_6821 obo:NCBITaxon_33154 obo:NCBITaxon_72041 obo:NCBITaxon_6681 obo:NCBITaxon_6656 obo:NCBITaxon_1206794 obo:NCBITaxon_6657 obo:NCBITaxon_88770 obo:NCBITaxon_33317 obo:NCBITaxon_2759 obo:NCBITaxon_354340 obo:NCBITaxon_6072'><span id='am-92' property="rdfs:label" content="Molina" datatype="xsd:string"></span><span id='am-93' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-94' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-95'  ></span>Molina</span> J, et al. Cure short- long-term experimental Chagas&#8217; disease <br />                                             using D0870. Science. 1996; 273:969&#8211;71. [PubMed: 8688084] <br />  <br />  <br />  <br />                                        Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01. <br />                             Lepesheva                                                                                                   Page 13 <br />  <br />  <br />                                         64. Williams KJ, Denning DW. Termination development D0870. J Antimicrob Chemother. <br />                                             2001; 47:720&#8211;1. [PubMed: 11328795] <br />                                         65. Diniz Lde F, Caldas IS, Guedes PM, et al. Effects ravuconazole treatment parasite load and <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             immune response dogs experimentally infected Trypanosoma cruzi. Antimicrob Agents <br />                                             Chemother. 2010; 54:2979&#8211;86. [PubMed: 20404124] <br />                                         66. Urbina JA. Ergosterol biosynthesis drug development Chagas disease. Mem Inst Oswaldo <br />                                             Cruz. 2009; 104(Suppl 1):311&#8211;18. [PubMed: 19753490] <br />                                         67. Dobish MC, Villalta F, Waterman MR, et al. Organocatalytic, enantioselective synthesis VNI: a <br />                                             robust therapeutic development platform Chagas, neglected tropical disease. Org Lett. 2012; <br />                                             14:6322&#8211;5. [PubMed: 23214987] <br />                                         68&#8226;. Pinazo MJ, <span id='am-108' about='obo:NCBITaxon_1118665' typeof='owl:Thing obo:NCBITaxon_33340 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_33154 obo:NCBITaxon_272259 obo:NCBITaxon_33317 obo:NCBITaxon_2759 obo:NCBITaxon_6960 obo:NCBITaxon_6072 obo:NCBITaxon_33208 obo:NCBITaxon_7422 obo:NCBITaxon_197562 obo:NCBITaxon_85512 obo:NCBITaxon_197563 obo:NCBITaxon_6656 obo:NCBITaxon_7496 obo:NCBITaxon_1206794 obo:NCBITaxon_88770 obo:NCBITaxon_272201 obo:NCBITaxon_7400 obo:NCBITaxon_7423 obo:NCBITaxon_33392 obo:NCBITaxon_7399 obo:NCBITaxon_50557'><span id='am-109'  ></span><span id='am-110' property="rdfs:label" content="Espinosa" datatype="xsd:string"></span><span id='am-111' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-112' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>Espinosa</span> G, Gallego M, et al. Successful treatment posaconazole patient <br />                                               chronic Chagas disease systemic lupus erythematosus. Am J Trop Med Hyg. 2010; <br />                                               82:583&#8211;7. Cure chronic chagasic patient posaconazole. [PubMed: 20348503] <br />                                         69. Clayton J. Chagas disease: pushing pipeline. Nature. 2010; 465:S12&#8211;15. [PubMed: <br />                                             20571548] <br />                                         70. Lepesheva GI, Hargrove TY, Anderson S, et al. Structural insights inhibition sterol 14 <br />                                             alpha-demethylase human pathogen Trypanosoma cruzi. J Biol Chem. 2010; 285:25582&#8211;90. <br />                                             [PubMed: 20530488] <br />                                         71. Lepesheva GI, Park HW, Hargrove TY, et al. Crystal structures <span id='am-39' about='obo:NCBITaxon_5691' typeof='owl:Thing obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_39700 obo:NCBITaxon_33682 obo:NCBITaxon_5654 obo:NCBITaxon_5690 obo:NCBITaxon_2759 obo:NCBITaxon_5653'><span id='am-40' property="oboInOwl:hasRelatedSynonym" content="Trypanosoma (Trypanozoon) brucei" datatype="xsd:string"></span><span id='am-41' property="oboInOwl:hasRelatedSynonym" content="Trypanosoma brucei subgroup" datatype="xsd:string"></span><span id='am-42' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-43' property="rdfs:label" content="Trypanosoma brucei" datatype="xsd:string"></span><span id='am-44' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-45'  ></span>Trypanosoma brucei</span> sterol 14 <br />                                             alpha-demethylase implications selective treatment human infections. J Biol Chem. <br />                                             2010; 285:1773&#8211;80. [PubMed: 19923211] <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         72. Hargrove TY, Wawrzak Z, Liu J, et al. Substrate preferences catalytic parameters determined <br />                                             structural characteristics sterol 14&#945;-demethylase (CYP51) Leishmania infantum. J Biol <br />                                             Chem. 2011; 286:26838&#8211;48. [PubMed: 21632531] <br />                                         73. Lepesheva G, Hargrove T, Kleshchenko Y, et al. CYP51: major drug target cytochrome <br />                                             P450 <span id='am-101' about='obo:NCBITaxon_superfamily' typeof='owl:Thing NCBITaxon:_taxonomic_rank'><span id='am-102' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-103' property="rdfs:label" content="superfamily" datatype="xsd:string"></span>superfamily</span>. Lipids. 2008; 43:1117&#8211;25. [PubMed: 18769951] <br />                                         74. Hargrove TY, Wawrzak Z, Liu J, et al. Structural complex sterol 14&#945;-demethylase (CYP51) <br />                                             14&#945;-methylenecyclopropyl-&#916;7-24, 25-dihydrolanosterol. J Lipid Res. 2012; 53:311&#8211;20. <br />                                             [PubMed: 22135275] <br />                                         75. Konkle ME, Hargrove TY, Kleshchenko YY, et al. Indomethacin amides novel molecular <br />                                             scaffold targeting Trypanosoma cruzi sterol 14 alpha-demethylase. J Med Chem. 2009; <br />                                             52:2846&#8211;53. [PubMed: 19354253] <br />                                         76&#8226;. Villalta F, Dobish MC, Nde PN, et al. VNI cures acute chronic experimental Chagas disease. <br />                                               J Infect Dis. 2013; 208:504&#8211;11. Curative effect new experimental T.cruzi-specific CYP51 <br />                                               inhibitor VNI mice. [PubMed: 23372180] <br />                                         77. Andriani G, <span id='am-118' about='obo:NCBITaxon_694927' typeof='obo:NCBITaxon_37567 obo:NCBITaxon_30225 owl:Thing obo:NCBITaxon_33340 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_85604 obo:NCBITaxon_104431 obo:NCBITaxon_33154 obo:NCBITaxon_37570 obo:NCBITaxon_41191 obo:NCBITaxon_33317 obo:NCBITaxon_2759 obo:NCBITaxon_6072 obo:NCBITaxon_6960 obo:NCBITaxon_33208 obo:NCBITaxon_41196 obo:NCBITaxon_197562 obo:NCBITaxon_85512 obo:NCBITaxon_197563 obo:NCBITaxon_1001973 obo:NCBITaxon_41197 obo:NCBITaxon_6656 obo:NCBITaxon_7496 obo:NCBITaxon_7088 obo:NCBITaxon_1206794 obo:NCBITaxon_88770 obo:NCBITaxon_33392 obo:NCBITaxon_50557'><span id='am-119' property="rdfs:label" content="Amata" datatype="xsd:string"></span><span id='am-120' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-121'  ></span><span id='am-122' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>Amata</span> E, Beatty J, et al. Antitrypanosomal lead discovery: identification ligand- <br />                                             efficient inhibitor Trypanosoma cruzi CYP51 parasite growth. J Med Chem. 2013; <br />                                             56:2556&#8211;67. [PubMed: 23448316] <br />                                         78. Lepesheva GI, Waterman MR. Sterol 14alpha-demethylase (CYP51) therapeutic target for <br />                                             human trypanosomiasis leishmaniasis. Curr Top Med Chem. 2011; 11:2060&#8211;71. [PubMed: <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             21619513] <br />                                         79&#8226;. Hargrove TY, Kim K, Nazar&#233; Correia Soeiro M, et al. CYP51 structures structure-based <br />                                               development novel, pathogen-specific inhibitory scaffolds. Int J Parasitol Drugs Drug Resist. <br />                                               2012; 2:178&#8211;86. Initial steps CYP51 structure-based VNI scaffold development. [PubMed: <br />                                               23504044] <br />                                         80. Guengerich FP. Cytochrome P450s enzymes drug metabolism toxicity. AAPS J. <br />                                             2006; 8:E101&#8211;11. [PubMed: 16584116] <br />                                         81. Lepesheva GI, Waterman MR. Sterol 14alpha-demethylase cytochrome P450 (CYP51), P450 in <br />                                             biological kingdoms. Biochim Biophys Acta. 2007; 1770:467&#8211;77. [PubMed: 16963187] <br />                                         82. Molina J, Brener Z, Romanha AJ, et al. In vivo activity bis-triazole D0870 drug- <br />                                             susceptible drug-resistant strains protozoan parasite Trypanosoma cruzi. J Antimicrob <br />                                             Chemother. 2000; 46:137&#8211;40. [PubMed: 10882704] <br />                                         83. Molina J, Martins-Filho O, Brener Z, et al. Activities triazole derivative SCH 56592 <br />                                             (posaconazole) drug-resistant strains protozoan parasite Trypanosoma <br />  <br />  <br />                                        Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01. <br />                             Lepesheva                                                                                                 Page 14 <br />  <br />  <br />                                             (<span id='am-113' about='obo:NCBITaxon_47570' typeof='owl:Thing obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_33682 obo:NCBITaxon_5654 obo:NCBITaxon_5690 obo:NCBITaxon_2759 obo:NCBITaxon_5653'><span id='am-114' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-115' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-116' property="rdfs:label" content="Schizotrypanum" datatype="xsd:string"></span><span id='am-117'  ></span>Schizotrypanum</span>) cruzi immunocompetent immunosuppressed murine hosts. Antimicrob <br />                                             Agents Chemother. 2000; 44:150&#8211;5. [PubMed: 10602737] <br />                                         84. Soeiro, MdNC.; Souza, EM.; da Silva, CF., et al. Antiparasitic activity sterol 14&#945;- <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             demethylase (CYP51) inhibitor VNI drug-resistant strains Trypanosoma cruzi: vitro <br />                                             vivo studies. Antimicrob Agents Chemother. 2013; 57(9):4151&#8211;63. [PubMed: 23774435] <br />                                         85. Kawashita SY, Sanson GFO, Fernandes O, et al. Maximum-likelihood divergence date estimates <br />                                             based rRNA gene sequences suggest scenarios Trypanosoma cruzi intraspecific <br />                                             evolution. Mol Biol Evol. 2001; 18:2250&#8211;9. [PubMed: 11719574] <br />                                         86. Benaim G, Sanders JM, <span id='am-1' about='obo:NCBITaxon_316718' typeof='owl:Thing obo:NCBITaxon_78536 obo:NCBITaxon_3646 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_3398 obo:NCBITaxon_1437183 obo:NCBITaxon_33090 obo:NCBITaxon_235631 obo:NCBITaxon_3977 obo:NCBITaxon_91827 obo:NCBITaxon_131221 obo:NCBITaxon_71240 obo:NCBITaxon_58024 obo:NCBITaxon_1437201 obo:NCBITaxon_58023 obo:NCBITaxon_91835 obo:NCBITaxon_235892 obo:NCBITaxon_2759 obo:NCBITaxon_35493 obo:NCBITaxon_71275 obo:NCBITaxon_3193'><span id='am-2' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-3' property="rdfs:label" content="Garcia" datatype="xsd:string"></span><span id='am-4'  ></span><span id='am-5' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>Garcia</span>-March&#225;n Y, et al. Amiodarone intrinsic anti-Trypanosoma <br />                                             cruzi activity acts synergistically posaconazole. J Med Chem. 2006; 49:892&#8211;9. [PubMed: <br />                                             16451055] <br />                                         87&#8226;. Soeiro MN, Castro SL. Trypanosoma cruzi targets new chemotherapeutic approaches. <br />                                               Expert Opin Ther Targets. 2009; 13:105&#8211;21. The paper provides deetailed review potential <br />                                               alternative drug targets T. cruzi. [PubMed: 19063710] <br />                                         88. Soeiro MNC, Werbovetz K, Boykin DW, et al. Novel amidines analogues promising agents <br />                                             intracellular parasites: systematic review. Parasitology. 2013; 140:929&#8211;51. [PubMed: <br />                                             23561006] <br />                                         89. Chatelain E, Ioset JR. Drug discovery development neglected diseases: DNDi model. <br />                                             Drug Des Devel Ther. 2011; 5:175&#8211;81. <br />                                         90. Keenan M, Abbott MJ, Alexander PW, et al. Analogues fenarimol potent inhibitors of <br />                                             Trypanosoma cruzi efficacious murine model Chagas disease. J Med Chem. 2012; <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             55:4189&#8211;204. [PubMed: 22536986] <br />                                         91. Hargrove TY, Wawrzak Z, Alexander P, et al. T. cruzi CYP51 complexes pyridine-based <br />                                             drug candidates Chagas disease: structural basis pathogen-selectivity. J Biol Chem. 2013 <br />                                             Epub ahead print. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                        Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01. <br />                             Lepesheva                                                                                              Page 15 <br />  <br />  <br />                                                                                 Article highlights <br />                                               &#8226;    Broader use antiparasitic therapy treat intermediate chronic forms of <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                    Chagas disease brings positive results, supporting concept should <br />                                                    treated infection cured. <br />                                               &#8226;    Current clinical drugs, benznidazole nifurtimox, however, toxic <br />                                                    better agents needed. <br />                                               &#8226;    To date, inhibitors sterol 14&#945;-demethylase (CYP51) advanced <br />                                                    new drug candidates: antifungal azoles, posaconazole ravuconazole are <br />                                                    evaluated clinical trials. <br />                                               &#8226;    Repurposing clinical antifungal drugs market for <br />                                                    indication cost-efficient way add arsenal available <br />                                                    antichagasic chemotherapy; however, selected inhibitors fungal <br />                                                    CYP51, certain limitations. <br />                                               &#8226;    Availability X-ray structure T. cruzi CYP51, complexes novel <br />                                                    experimental protozoa-specific CYP51 inhibitors active vivo makes <br />                                                    lead optimization process straightforward. <br />                                               &#8226;    Including novel drug candidates, VNI derivatives, sphere <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                    of drug developing companies highly helpful advancing <br />                                                    passage clinical trials. <br />                                         This box summarizes key points contained article. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                        Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01. <br />                             Lepesheva                                                                                       Page 16 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         Figure 1. Compounds active T. cruzi <br />                                         A. Nitroheterocycles: antichagasic drugs benznidazole nifurtimox experimental <br />                                         compound 42 ref [43]. B. Antifungal drugs drug candidates. C. Examples of <br />                                         experimental inhibitors T. cruzi CYP51. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                        Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01. <br />                             Lepesheva                                                                                           Page 17 <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         Figure 2. T. cruzi CYP51 structure template rational drug design <br />                                         The orientation protein panels similar (~ distal view P450 molecule). A. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         CYP51-structure-based inhibitory pharmacophore including imidazoles VNI (cyan, PDB ID <br />                                         [3gw9]), VNF (brick, [3skw]), NEE (purple, [4h6o]); triazoles posaconazole (blue, <br />                                         [3k1o]), fluconazole (pink, [3lfd]); pyridine derivative UDO (goldenrod, [3zg2]) and <br />                                         substrate analog MCP (olive, [3p99]). B. Overall semitransparent surface representation of <br />                                         CYP51 molecule, enlarged view secondary structural elements forming the <br />                                         substrate access channel binding cavity seen c. C. The secondary <br />                                         structural elements forming entrance substrate binding channel colored in <br />                          <br /> </body></html>